CRO adds large molecule services to US laboratory

Stated in a recent press release, PRA announced that it will add immunochemistry services to its Kansas laboratory.

PRA, a CRO focusing on clinical trial solutions, has recently announced in a press release that as well as providing full service bioanalytical capabilities in its Assen (The Netherlands) laboratory, it will now offer immunochemistry services in its Lenexa (KS, USA) laboratory. The laboratory facilities provided by the CRO, in both The Netherlands and the US are located nearby to the clinical facilities, the CRO therefore claims rapid results from Phase I clinical studies.

Chad Briscoe, PRA executive director, Science and Innovations, Bioanalytical Laboratories commented, “By expanding our services to large molecule bioanalysis, we can now support all types of clinical trials. It is an important addition to our services because the contribution of large molecules in drug research and the development of biosimilars have increased rapidly over the past few years.”

PRA’s Early Development Services group consisting of 1000 staff, 500 beds, eight clinics and two laboratories, provides compound development and testing in both healthy volunteers and patients.

Source: PRA adds large molecule capabilities to US laboratory.